Verastem (GB:0LOV)

Verastem (0LOV) Share Price & Analysis


0LOV Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$4.44 - $15.12
Previous Close$7.43
Average Volume (3M)315.00
Market Cap
Enterprise Value$62.34M
Total Cash (Recent Filing)$165.66M
Total Debt (Recent Filing)$42.04M
Price to Earnings (P/E)N/A
Mar 12, 2024
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
Shares Outstanding25,267,436
10 Day Avg. Volume2,798
30 Day Avg. Volume315
Standard Deviation0.23
Financial Highlights & Ratios
Price to Book (P/B)2.24
Price to Sales (P/S)49.43
Price to Cash Flow (P/CF)-2.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit24.01
Enterprise Value/Ebitda-1.15
Price Target Upside275.77% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6



Ownership Overview

0.00% Mutual Funds
52.71% Other Institutional Investors
47.29% Public Companies and
Individual Investors


What was Verastem’s price range in the past 12 months?
Verastem lowest share price was $4.44 and its highest was $15.12 in the past 12 months.
    What is Verastem’s market cap?
    Currently, no data Available
    When is Verastem’s upcoming earnings report date?
    Verastem’s upcoming earnings report date is Mar 12, 2024 which is in 92 days.
      How were Verastem’s earnings last quarter?
      Verastem released its earnings results on Nov 08, 2023. The company reported -$0.75 earnings per share for the quarter, beating the consensus estimate of -$0.843 by $0.093.
        Is Verastem overvalued?
        According to Wall Street analysts Verastem’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Verastem pay dividends?
          Verastem does not currently pay dividends.
          What is Verastem’s EPS estimate?
          Verastem’s EPS estimate is -$0.64.
            How many shares outstanding does Verastem have?
            Currently, no data Available
            What happened to Verastem’s price movement after its last earnings report?
            Verastem reported an EPS of -$0.75 in its last earnings report, beating expectations of -$0.843. Following the earnings report the stock price went same 0%.
              Which hedge fund is a major shareholder of Verastem?
              Among the largest hedge funds holding Verastem’s share is Viking Global Investors LP. It holds Verastem’s shares valued at 20M.

                Company Description


                Verastem, Inc., operating as Verastem Oncology, is a biopharmaceutical company focusing on developing and commercializing medicines to improve the survival and quality of life of cancer patients. It markets COPIKTRA™ (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K) and dual inhibitor of PI3K-delta and PI3K-gamma, which is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies. The indication in FL is approved under accelerated approval based on overall response rate. In addition, it is developing the focal adhesion kinase inhibitor defactinib, which is being evaluated in three separate clinical collaborations in combination with immunotherapeutic agents for the treatment of various different cancer types, including pancreatic cancer, ovarian cancer, non-small cell lung cancer (NSCLC), and mesothelioma. Verastem, Inc. has collaboration agreements with Yakult Honsha Co., Ltd., CSPS Pharmaceutical Group Limited and The Leukemia & Lymphoma Society. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.

                Forecast EPS vs Actual EPS

                Similar Stocks
                Price & Change
                Lexicon Pharmaceuticals
                Popular Stocks
                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis